Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone.
Humoral and cellular immune responses were followed in multiple sclerosis patients treated with Copolymer 1 (Cop1, glatiramer acetate, Copaxone) who participated in three different clinical trials. All patients (130) developed Cop1 reactive antibodies, which peaked at 3 months after initiation of treatment, decreasing at 6 months and remaining low. IgG1 antibody levels were 2-3-fold higher than those of IgG2. The proliferative response of Peripheral Blood Mononuclear Cells (PBMC) to Cop1 was initially high and gradually decreased during treatment. Antibodies and T cell responses to MBP were low and did not change significantly during the treatment. The humoral and cellular immunological responses to Cop1 do not correlate with the side effects and do not affect its therapeutic activity. The preferential production of IgG1 over IgG2 antibodies may indicate that Th2 responses are involved in mediating the clinical effect of Cop1.
Brenner
T
T
Department of Neurology, Hadassah University Hospital, Jerusalem, Israel.
Arnon
R
R
Sela
M
M
Abramsky
O
O
Meiner
Z
Z
Riven-Kreitman
R
R
Tarcik
N
N
Teitelbaum
D
D
D000328:Adult; D000915:Antibody Affinity / Q000276:immunology; D002455:Cell Division / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D004676:Myelin Basic Protein / Q000276:immunology / Q000494:pharmacology; D010455:Peptides / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D012008:Recurrence; D012720:Severity of Illness Index; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
D007074:Immunoglobulin G; D004676:Myelin Basic Protein; D010455:Peptides; D000068717:Glatiramer Acetate